Based on the NMDAR dysfunction hypothesis, it has been proposed that inhibitors of the human D-aspartate oxidase (hDASPO) [24] could represent a potentially innovative strategy to counteract the loss of response to antipsychotics in schizophrenia. The gene discussed is DDO; the disease is schizophrenia.